RAP-103 (Clarent Biopharma Inc)

RAP-103 is an orally active, stabilized pentapeptide analog of D-ala-peptide T-amide (DAPTA) that functions as a multi-chemokine receptor antagonist. Developed by Clarent Biopharma, it specifically targets the CCR2, CCR5, and CCR8 receptors to modulate inflammatory responses. The drug is primarily being investigated for the treatment of moderate to severe plaque psoriasis, with Phase 2 clinical trials evaluating its efficacy in improving Psoriasis Area and Severity Index (PASI) scores and patient quality of life. As a peptide-based therapeutic, RAP-103 balances the innate immune system's inflammatory response by blocking specific chemokine hormones.

Other names

D-ala-peptide T-amide analogpentapeptide analog of DAPTA